Promising combo for tough breast cancer hits snag: trial withdrawn
NCT ID NCT07134556
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 23 times
Summary
This study aimed to test a combination of three drugs (zimberelimab, domvanalimab, and sacituzumab govitecan) as a first treatment for people with advanced triple-negative breast cancer that shows a specific marker (PD-L1 positive). The goal was to see if the combo could shrink tumors and slow the disease. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.